Skye Bioscience Reports 52-Week Efficacy Data for Nimacimab
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 02 2026
0mins
Should l Buy SKYE?
Skye Bioscience announced interim 52-week data from the combination therapy arms in the extension phase of the Phase 2a CBeyond proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody. The blinded extension of the CBeyond study for combination cohorts was opened in May 2025 for participants assigned to either nimacimab plus semaglutide or placebo plus semaglutide arms. Of the 9 participants in the placebo plus semaglutide arm that joined the extension study, mean weight loss at 26 weeks was 13.9%. Seven participants completed treatment of the additional 26 weeks and lost an additional 5.8% of weight during the extension period, resulting in a mean weight loss of 19.7% after 52 weeks of treatment. In October 2025, Skye reported top-line 26-week data from CBeyond showing that the nimacimab and semaglutide combination cohort achieved clinically meaningful weight loss compared with semaglutide alone, with no plateau observed.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SKYE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SKYE
Wall Street analysts forecast SKYE stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.625
Low
10.00
Averages
14.33
High
20.00
Current: 0.625
Low
10.00
Averages
14.33
High
20.00
About SKYE
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Skye Bioscience Q4 2025 Earnings Call Insights
- Clinical Progress: Skye Bioscience's nimacimab demonstrated a 3% weight loss improvement at 26 weeks when combined with semaglutide, achieving a 22.3% mean weight loss after 52 weeks, indicating its potential in weight management therapies and opening new market opportunities for the company.
- Expansion Study Plans: The company is initiating the CBeyond expansion study to evaluate higher doses of nimacimab, planning to advance subcutaneous delivery via Halozyme's ENHANZE technology in preparation for the Phase IIb trial, which could enhance the product's competitive edge in the market.
- Financial Position: As of year-end 2025, Skye Bioscience reported $25.7 million in cash and short-term investments, with a managed operating plan extending the runway through Q4 2026, ensuring funding for critical clinical trials and operational needs.
- Future Outlook: Management anticipates several key catalysts in 2026, including interim data from the CBeyond expansion study and FDA meeting minutes, reflecting the company's confidence in its clinical development and regulatory readiness.
See More
Skye Bioscience Q4 Earnings Miss Expectations
- Earnings Performance: Skye Bioscience reported a Q4 GAAP EPS of -$0.36, missing expectations by $0.06, indicating challenges in profitability that may affect investor confidence.
- Cash Reserves: As of December 31, 2025, the company had $25.7 million in cash, cash equivalents, and short-term investments, which, while providing some liquidity, raises concerns about its ongoing operational viability.
- Increased Net Loss: The net loss for Q4 2025 totaled $14.4 million, significantly higher than the $9.7 million reported in the same period of 2024, reflecting pressure on the company's cost control and revenue growth.
- Share-Based Compensation Adjustments: Non-cash share-based compensation expenses were $1.6 million, down from $2.1 million in Q4 2024, suggesting adjustments in the compensation structure to address financial pressures.
See More
Skye Bioscience to Announce Q4 Earnings on March 9
- Earnings Announcement Schedule: Skye Bioscience is set to release its Q4 earnings report on March 9, after market close, drawing significant attention from market participants regarding its performance.
- Earnings Expectations: Analysts have a consensus EPS estimate of -$0.31, representing a 29.2% year-over-year decline, indicating the financial pressures the company is currently facing.
- Revenue Forecast: The consensus revenue estimate for Skye Bioscience stands at $0, suggesting that the company may not achieve sales growth in the current fiscal quarter.
- Historical Financial Data: Investors can refer to Skye Bioscience's historical financial data to assess performance trends and future potential.
See More
Skye Bioscience Reports Interim Data from Nimacimab Study
- Clinical Trial Progress: Skye Bioscience's Phase 2a CBeyond study for obesity shows significant results with nimacimab combined with GLP-1R agonist (Wegovy), achieving an average weight loss of 14.4% at 26 weeks and 22.3% at 52 weeks, indicating the therapy's potential in weight management.
- Safety Assessment: The extension study reported no serious adverse events for the nimacimab and semaglutide combination, demonstrating good tolerability and safety, which bolsters confidence for future clinical applications.
- Comparative Analysis: The combination therapy group lost 13.2% of weight at 26 weeks compared to 10.25% in the semaglutide-only control group, suggesting that the combination may offer more durable weight loss effects.
- Future Outlook: Topline data from the CBeyond Phase 2a extension is expected in Q3 2026, with analyst William Blair noting that supportive data could attract investor interest, despite a current stock price decline of 5.53%.
See More
Skye Bioscience Reports Positive Clinical Data from Nimacimab Study
- Clinical Trial Results: Skye Bioscience's CBeyond Phase 2a study shows that the combination of nimacimab and semaglutide achieved a significant 22.3% weight loss over 52 weeks, highlighting the therapy's efficacy and potential market competitiveness.
- Durability Advantage: During the 13-week off-therapy follow-up, the nimacimab plus semaglutide cohort regained only 17.8% of lost weight compared to 37.3% for semaglutide alone, indicating a superior durability advantage of the combination therapy.
- Safety Assessment: The combination therapy demonstrated good tolerability at tested doses during the extension study, with no serious adverse events reported, further enhancing the therapy's market appeal.
- Future Outlook: Skye anticipates that optimized dosing of nimacimab in future clinical trials could lead to even deeper weight loss, showcasing the company's long-term growth potential in the obesity treatment sector.
See More
Skye Bioscience to Present Nimacimab Efficacy Study at Keystone Conference
- Clinical Research Presentation: Skye Bioscience will present its study on the obesity-targeting antibody nimacimab at the Keystone conference on January 28, 2026, exploring its effects on weight loss at various doses, aiming to provide new insights for obesity treatment.
- Mechanism Exploration: The research will assess whether nimacimab can serve as a maintenance therapy after discontinuation of tirzepatide and whether its weight loss effects primarily rely on caloric restriction, thus providing crucial data support for clinical applications.
- Innovative Drug Characteristics: Nimacimab, as a peripherally-restricted monoclonal antibody, is designed to avoid central nervous system penetration, potentially reducing the neuropsychiatric side effects commonly associated with small-molecule antagonists, showcasing its unique advantages in obesity treatment.
- Clinical Trial Progress: Skye is currently conducting a Phase 2a clinical trial for nimacimab in combination with the GLP-1R agonist Wegovy®, which will provide empirical support for its market potential in the obesity sector.
See More
Skye Bioscience Q4 2025 Earnings Call Insights
- Clinical Progress: Skye Bioscience's nimacimab demonstrated a 3% weight loss improvement at 26 weeks when combined with semaglutide, achieving a 22.3% mean weight loss after 52 weeks, indicating its potential in weight management therapies and opening new market opportunities for the company.
- Expansion Study Plans: The company is initiating the CBeyond expansion study to evaluate higher doses of nimacimab, planning to advance subcutaneous delivery via Halozyme's ENHANZE technology in preparation for the Phase IIb trial, which could enhance the product's competitive edge in the market.
- Financial Position: As of year-end 2025, Skye Bioscience reported $25.7 million in cash and short-term investments, with a managed operating plan extending the runway through Q4 2026, ensuring funding for critical clinical trials and operational needs.
- Future Outlook: Management anticipates several key catalysts in 2026, including interim data from the CBeyond expansion study and FDA meeting minutes, reflecting the company's confidence in its clinical development and regulatory readiness.
See More
Skye Bioscience Q4 Earnings Miss Expectations
- Earnings Performance: Skye Bioscience reported a Q4 GAAP EPS of -$0.36, missing expectations by $0.06, indicating challenges in profitability that may affect investor confidence.
- Cash Reserves: As of December 31, 2025, the company had $25.7 million in cash, cash equivalents, and short-term investments, which, while providing some liquidity, raises concerns about its ongoing operational viability.
- Increased Net Loss: The net loss for Q4 2025 totaled $14.4 million, significantly higher than the $9.7 million reported in the same period of 2024, reflecting pressure on the company's cost control and revenue growth.
- Share-Based Compensation Adjustments: Non-cash share-based compensation expenses were $1.6 million, down from $2.1 million in Q4 2024, suggesting adjustments in the compensation structure to address financial pressures.
See More
Skye Bioscience to Announce Q4 Earnings on March 9
- Earnings Announcement Schedule: Skye Bioscience is set to release its Q4 earnings report on March 9, after market close, drawing significant attention from market participants regarding its performance.
- Earnings Expectations: Analysts have a consensus EPS estimate of -$0.31, representing a 29.2% year-over-year decline, indicating the financial pressures the company is currently facing.
- Revenue Forecast: The consensus revenue estimate for Skye Bioscience stands at $0, suggesting that the company may not achieve sales growth in the current fiscal quarter.
- Historical Financial Data: Investors can refer to Skye Bioscience's historical financial data to assess performance trends and future potential.
See More
Skye Bioscience Reports Interim Data from Nimacimab Study
- Clinical Trial Progress: Skye Bioscience's Phase 2a CBeyond study for obesity shows significant results with nimacimab combined with GLP-1R agonist (Wegovy), achieving an average weight loss of 14.4% at 26 weeks and 22.3% at 52 weeks, indicating the therapy's potential in weight management.
- Safety Assessment: The extension study reported no serious adverse events for the nimacimab and semaglutide combination, demonstrating good tolerability and safety, which bolsters confidence for future clinical applications.
- Comparative Analysis: The combination therapy group lost 13.2% of weight at 26 weeks compared to 10.25% in the semaglutide-only control group, suggesting that the combination may offer more durable weight loss effects.
- Future Outlook: Topline data from the CBeyond Phase 2a extension is expected in Q3 2026, with analyst William Blair noting that supportive data could attract investor interest, despite a current stock price decline of 5.53%.
See More
Skye Bioscience Reports Positive Clinical Data from Nimacimab Study
- Clinical Trial Results: Skye Bioscience's CBeyond Phase 2a study shows that the combination of nimacimab and semaglutide achieved a significant 22.3% weight loss over 52 weeks, highlighting the therapy's efficacy and potential market competitiveness.
- Durability Advantage: During the 13-week off-therapy follow-up, the nimacimab plus semaglutide cohort regained only 17.8% of lost weight compared to 37.3% for semaglutide alone, indicating a superior durability advantage of the combination therapy.
- Safety Assessment: The combination therapy demonstrated good tolerability at tested doses during the extension study, with no serious adverse events reported, further enhancing the therapy's market appeal.
- Future Outlook: Skye anticipates that optimized dosing of nimacimab in future clinical trials could lead to even deeper weight loss, showcasing the company's long-term growth potential in the obesity treatment sector.
See More
Skye Bioscience to Present Nimacimab Efficacy Study at Keystone Conference
- Clinical Research Presentation: Skye Bioscience will present its study on the obesity-targeting antibody nimacimab at the Keystone conference on January 28, 2026, exploring its effects on weight loss at various doses, aiming to provide new insights for obesity treatment.
- Mechanism Exploration: The research will assess whether nimacimab can serve as a maintenance therapy after discontinuation of tirzepatide and whether its weight loss effects primarily rely on caloric restriction, thus providing crucial data support for clinical applications.
- Innovative Drug Characteristics: Nimacimab, as a peripherally-restricted monoclonal antibody, is designed to avoid central nervous system penetration, potentially reducing the neuropsychiatric side effects commonly associated with small-molecule antagonists, showcasing its unique advantages in obesity treatment.
- Clinical Trial Progress: Skye is currently conducting a Phase 2a clinical trial for nimacimab in combination with the GLP-1R agonist Wegovy®, which will provide empirical support for its market potential in the obesity sector.
See More
